Rockwell Medical (RMTI) to Release Earnings on Monday

Rockwell Medical (NASDAQ:RMTI) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Rockwell Medical to post earnings of ($0.03) per share and revenue of $17.46 million for the quarter. Rockwell Medical has set its FY 2025 guidance at EPS.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. The business had revenue of $24.67 million during the quarter, compared to analyst estimates of $23.65 million. On average, analysts expect Rockwell Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rockwell Medical Trading Down 4.7 %

NASDAQ RMTI opened at $1.12 on Friday. Rockwell Medical has a 1 year low of $0.86 and a 1 year high of $5.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 2.00. The company has a market capitalization of $38.11 million, a PE ratio of -22.30 and a beta of 1.64. The company has a fifty day moving average of $1.23 and a 200 day moving average of $1.97.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their price objective on Rockwell Medical from $7.00 to $3.00 and set a “buy” rating for the company in a report on Monday, March 24th.

Insider Transactions at Rockwell Medical

In other Rockwell Medical news, major shareholder Larson Family Inve Irrevocable acquired 57,000 shares of the business’s stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.07 per share, for a total transaction of $60,990.00. Following the completion of the transaction, the insider now directly owns 3,527,000 shares of the company’s stock, valued at $3,773,890. This represents a 1.64 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 10,680 shares of company stock valued at $11,552 in the last 90 days. 1.90% of the stock is currently owned by company insiders.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.